Kite Pharma, Inc.KITE announced that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has adopted positive opinions in favor of granting orphan drug status to the company’s lead pipeline candidate, KTE C19, for the treatment of
Kite (KITE) KTE-C19 Endorsed for EU Orphan Status Yet Again
